Karyopharm Reports First Quarter 2024 Financial Results and ...

Total revenue for the first quarter of 2024 was $33.1 million, compared to $38.7 million for the first quarter of 2023.

Karyopharm Therapeutics Reports Q1 2024 Financial Results

Financial Performance Highlights. For Q1 2024, Karyopharm reported a total revenue of $33.1 million, a decrease from the $38.7 million recorded ...

Karyopharm to Report First Quarter 2024 Financial Results on May 8 ...

NEWTON, Mass., May 2, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer ...

Karyopharm Reports First Quarter 2024 Financial Results and ...

Total revenue for the first quarter of 2024 was $33.1 million, compared to $38.7 million for the first quarter of 2023.

Press Releases - Investor Relations | Karyopharm Therapeutics

Jul 31, 2024. Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 · Jul 1, 2024. Karyopharm Therapeutics Reports Inducement Grants Under ...

Press Releases - Investor Relations | Karyopharm Therapeutics

– Achieves Second Quarter 2024 Total Revenue of $42.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.0 Million; Positive Momentum ex-US with ...

Karyopharm Q1 2024 Financial Results and Recent Progress

Karyopharm's financial results for the first quarter of 2024 revealed a net loss of $37.4 million, or $0.32 per share, compared to a net loss of ...

Karyopharm Reports Third Quarter 2024 Financial Results and ...

Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $29.5 Million; Continued Re.

Karyopharm Reports Third Quarter 2024 Financial Results and ...

Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $29.5 Million; ...

Investor Relations | Karyopharm Therapeutics - Corporate Profile

Karyopharm's lead compound and first ... Press Releases. Investor Alerts. Nov 5, 2024. Karyopharm Reports Third Quarter 2024 Financial Results and Highlights ...

Karyopharm to Report First Quarter 2024 Financial Results on May 8 ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it ...

First Quarter 2024 Financial Results & Business Update

XPOVIO® (selinexor) and NEXPOVIO® (selinexor) are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this ...

Karyopharm Reports Third Quarter 2024 Financial Results : r/KPTI

https://investors.karyopharm.com/2024-11-05-Karyopharm-Reports-Third-Quarter-2024-Financial-Results-and-Highlights-Recent-Company-Progress.

Karyopharm to Announce Q1 2024 Financial Results on May 8, 2024

Karyopharm Therapeutics Inc., a pharmaceutical company known for its innovative cancer treatments, announced that it will release its first ...

Akero Therapeutics Reports First Quarter 2024 Financial Results ...

General and administrative expenses for the three-month period ended March 31, 2024 were $9.3 million, compared to $7.0 million for the comparable period in ...

KPTI - Karyopharm Therapeutics Inc. Latest Stock News & Market ...

Financially, Karyopharm reported total revenue of $33.7 million for Q4 2023, with a full-year revenue of $146.0 million. Despite a competitive market, the ...

A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor ...

PRNewswire 2024 - Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress open_in_new ... "Achieved U.S. net product ...

Karyopharm Therapeutics Inc. Q3 2024 Financial Results

For the third quarter of 2024, Karyopharm reported a net loss of $32.1 million, or $0.26 per basic and diluted share, compared to a net loss of ...

KPTI / Karyopharm Therapeutics Inc. - SEC Filings, Annual Report ...

2024-02-29, Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress – Total Revenue of $146 Million and ...

Karyopharm to Report Second Quarter 2024 Financial Results on ...

Karyopharm Therapeutics to report Q2 2024 results on Aug 6. Join the conference call at 8:00 a.m. ET for financial updates and company ...